* Rhythm Pharmaceuticals Inc RYTM.OQ reported a quarterly
adjusted loss of $2.35 per share for the quarter ended in
March, lower than the same quarter last year, when the company
reported EPS of -92 cents. The mean expectation of
nine analysts for the quarter was for a loss of $2.16 per share.
Wall Street expected results to range from $-2.41 to -61 cents
per share.
* Revenue rose 126.4% to $25.97 million from a year ago;
analysts
expected $26.90 million.
* Rhythm Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $2.35.
* The company reported a quarterly loss of $141.37 million.
* Rhythm Pharmaceuticals Inc shares had risen by 1.3% this
quarter and lost 4.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 207.1% in the last three months.
* In the last 30 days, three analysts negatively revised
earnings
estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Rhythm
Pharmaceuticals Inc is $55.00
This summary was machine generated from LSEG data May 7 at 05:46
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -2.16 -2.35 Missed
Dec. 31 2023 -0.70 -0.70 Met
Sep. 30 2023 -0.74 -0.76 Missed
Jun. 30 2023 -0.79 -0.82 Missed